Traws Pharma Notified of Nasdaq Minimum Bid Non-Compliance

What Happened
Traws Pharma, Inc. (TRAW) filed an 8-K (filed July 31, 2026) reporting that on July 29, 2026 it received a Nasdaq notice saying the closing bid price for its common stock was below $1.00 per share for at least 30 consecutive business days and therefore it is not currently compliant with Nasdaq Listing Rule 5550(a)(2). The notice does not affect the Company’s current listing status; the listing remains fully effective while the Company works to regain compliance.

Key Details

• Nasdaq found Traws’ closing bid price below $1.00 for at least 30 consecutive business days (notice dated July 29, 2026).
• The initial compliance period is 180 calendar days from July 29, 2026, ending January 25, 2027.
• To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days (Nasdaq may extend this to up to 20 consecutive business days).
• If not regained, Nasdaq may grant a second 180-day grace period only if the company meets market value/public float and other initial listing standards (except the minimum bid) and notifies Nasdaq of its intent to cure; failure could lead to delisting, subject to appeal to a Nasdaq hearings panel.

Why It Matters
This notice signals a material listing risk: if Traws does not meet the bid-price requirement within the allowed periods, Nasdaq could move to delist the stock, which can reduce liquidity and make trading more difficult for retail investors. The company’s listing is currently unaffected, and Traws says it will monitor the share price and consider options to regain compliance. Investors should be aware of the timeline (through Jan 25, 2027 for the first period) and monitor any further announcements about stock price recovery, compliance actions, or Nasdaq rulings.